Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen L. Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain
Abstract
A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.
Topics & Concepts
BevacizumabInfiltration (HVAC)Triple-negative breast cancerMedicineBreast cancerCD8Immune systemEffectorCancer researchImmunotherapyChemotherapyInternal medicineImmunologyCancerPhysicsThermodynamicsImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer